MedTrace Logo

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 760

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Conditions

Interventions

DRUG

Dapirolizumab pegol

Subjects will receive dapirolizumab pegol at prespecified time-points.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2030-08-07
Completion
2030-08-07
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Belgium
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Italy
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Puerto Rico
  • Romania
  • Serbia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976322 on ClinicalTrials.gov